Compare SACH & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | QNCX |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 139.2M |
| IPO Year | 2017 | 2019 |
| Metric | SACH | QNCX |
|---|---|---|
| Price | $1.18 | $4.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $7.75 |
| AVG Volume (30 Days) | 232.7K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 16.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,906,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.72 |
| 52 Week High | $1.40 | $4.55 |
| Indicator | SACH | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 75.56 |
| Support Level | $1.00 | $3.74 |
| Resistance Level | $1.16 | $4.30 |
| Average True Range (ATR) | 0.05 | 0.46 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 69.57 | 86.67 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.